admin – ទំព័រ 50

Posts by admin:

Quam Plus Financial Group and Dinosaur Financial Group Announce Strategic Partnership to Expand Cross-Border Capital Markets Access

ខែមីនា 2, 2026 admin

Hong Kong, New York, London, Mar 2, 2026 - (ACN Newswire via SeaPRwire.com) - Quam Plus International Financial Limited (“Quam Plus”), through its wholly owned subsidiary Quam Securities Limited (together, the “Quam Plus Financial Group”) has announced a strategic investment by and collaborative partnership with Dinosaur Financial Group, LLC (“DFG”), a global investment banking and financial services firm, aimed at leveraging complementary capabilities across Asia, the United States, and Europe. The partnership is designed to create a cooperative platform across three of the world’s most important financial centres — Hong Kong, New York, and London — enabling both firms to enhance their international reach, broaden product distribution, and jointly serve clients seeking cross-border capital markets access.Under the collaboration, Quam Securities will benefit from expanded access to U.S. and European markets through Dinosaur’s established infrastructure and regulatory footprint, while Dinosaur will strengthen its Asia-Pacific presence by leveraging Quam Securities’ deep regional expertise, client relationships, and distribution capabilities. The partnership is expected to support capital raising, advisory, execution, and investment opportunities for clients across multiple jurisdictions.Both Quam Plus Financial Group and DFG are members of Global Alliance Partners (GAP), a Hong Kong based global network of independent investment banks, further reinforcing their shared commitment to global collaboration and best-in-class client service.Commenting on the partnership, Kenneth Lam, Co-Chairman and Chief Executive Officer of Quam Plus Financial Group, said:“This strategic relationship with DFG aligns closely with Quam Securities’ long-term international development strategy. By combining our strong Asia-Pacific franchise with Dinosaur’s U.S. and European capabilities, we are well positioned to enhance our service offering and support clients pursuing global growth opportunities. We believe this partnership will meaningfully strengthen our cross-border execution and advisory capabilities.”Glenn Grossman, Chief Executive Officer of DFG, said:“Partnering with Quam Securities provides DFG with a powerful platform to deepen our presence in Asia, particularly Greater China, alongside a well-established and respected Hong Kong-listed institution. This collaboration reflects our shared focus on strategic growth, disciplined execution, and delivering differentiated solutions for clients operating in the world’s fastest growing and most dynamic markets.”The firms will work closely to identify and develop joint opportunities across investment banking, capital markets, trading, and wealth and asset management, with a focus on offering complementary, non-overlapping services to institutional and qualified clients globally.About Quam Plus Financial Group and Quam SecuritiesQuam Plus is listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 952) in 1997. Quam Plus Financial Group is a Hong Kong based financial services group committed to building a comprehensive, full-licensed integrated financial platform. Quam Securities is one of its key member companiesQuam Plus Financial Group is principally engaged in (i) corporate finance advisory and general advisory services; (ii) fund management, discretionary portfolio management and portfolio management advisory services; (iii) discretionary and non-discretionary dealing services for securities, futures and options, securities placing and underwriting services, margin financing, insurance broking and wealth management services; (iv) money lending services; (v) financial media services; and (vi) investing and trading of various investment products.About Dinosaur Group Holdings (DGH) and DFGDinosaur Group Holdings (DGH) is the holding company for DFG, an investment firm registered with the SEC and a member of FINRA and SIPC, Dinosaur Merchant Bank Ltd. (regulated by the FCA) and New York-based SEC-registered investment firm DCM Advisors, LLC. Deploying a team of approximately 120 professionals, the overall organization provides global execution services, financing and advisory expertise/insights for equities, fixed income, commodities and derivatives, investment management as well as a suite of investment banking services providing financial solutions and capital markets execution to the middle market client base, both domestically and globally. Clients and counterparties spanning six continents are primarily institutions, family offices, asset managers, hedge funds, and corporations. Dinosaur Group takes pride in the business’ stable management, strong compliance, solid operations, and diverse talent.Dinosaur Financial Group is a global financial services firm providing investment banking and advisory services, prime brokerage, global trading, private wealth and custodial services, and asset management.Media Contacts:Quam Plus Financial GroupMandy Lo, Marketing & Corporate Communications DirectorCharlie Chan, Marketing & PR ManagerEmail: mandy.lo@quamgroup.com charlie.chan@quamgroup.comDinosaur Financial GroupAmit Sangekar, Chief Marketing OfficerEmail: asangekar@dinogroup.co.uk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

នៅប៉ាគីស្ថាន មានក្រហមណ៏យោគជិត ២២ នាក់ និងរងរន្ធនៅច្រើនពី ១២០ នាក់ ក្រោយពីអ្នកត្រូវបានគាំទ្រអ៊ីរ៉ង់ ព្យាយាមធ្វើឱ្យបំផ្លិចបំពង់ស្ថានប្រមាណអាមេរិក

ខែមីនា 2, 2026 admin

(SeaPRwire) - ការជ្រះជ្រើនឃ្លាំងរវាងអ្នកប示威 និងកម្មforcesង្គោះសន្តិសុខនៅទីក្រុងព្រំប្រទេសប៉ាគីស្ថាននៅភាគខាងត្បូងនៃការ៉ាជី និងនៅភាគខាងជើងនៃប្រទេសបានធ្វើឱ្យមនុស្សយ៉ាងហោចណាស់22នាក់ស្លាប់ និងមនុស្សជាង120នាក់រងរបួស នៅពេលអ្នកប示威ដែលគាំទ្ររដ្ឋអាហ្រណ៍អ៊ីរ៉ង់បានព្យាយាមធ្វើឱ្យចូលដល់ការិយាល័យអាមេរិកនៅថ្ងៃអាទិត្យ ដោយមន្រ្តីពង្រឹងបាននិយាយ។នៅភាគខាងជើងនៃប្រទេស ប្រជនប示威បានវាយប្រហារការិយាល័យអង្គការសហប្រជាជន និងរដ្ឋាភិបាល។ការហឹង្សាហឹង្សាបានកើតឡើងបន្ទាប់ពី ការសម្លាប់ នាយកអធិរាជអ៊ីរ៉ង់។ ពង្រឹងប៉ូលីស និងមន្រ្តីក្នុងមន្ទីរពេទ្យនៅការ៉ាជីបាននិយាយថា មនុស្សយ៉ាងហោចណាស់ទៅ50នាក់ក៏រងរបួសក្នុងការជ្រះជ្រើន ហើយអ្នកខ្លះកំពុងស្ថិតក្នុងស្ថានភាពធ្ងន់ធ្ងរ។ប្រធានាធិបតី អាស៊ីហ្វីអាលីហ្សាដារីបានបង្ហាញការសង្ឃឹមខ្លាំងរបស់គាត់ “ចំពោះការស្លាប់ដោយសង្គ្រាម” នៃខាមេណី និងបានផ្តល់សំណាធិសាស្តុការចំពោះរដ្ឋអាហ្រណ៍អ៊ីរ៉ង់ យោងតាមការិយាល័យរបស់គាត់។ គាត់បាននិយាយថា៖ “ប៉ាគីស្ថានស្ថិតជាមួយជនជាតិអ៊ីរ៉ង់នៅពេលការឈឺក្នុងនេះ និងចែករំលែកការបាត់បង់របស់ពួកគេ។”ស៊ូម៉ាយ៉ា ស៊ីដតារីក គ្រូពេទ្យប៉ូលីសនៅមន្ទីរពេទ្យរដ្ឋាភិបាលចំនួនមួយនៅការ៉ាជី បានបញ្ជាក់ថា សព្ទ6នាក់ និងមនុស្សរងរបួសជាច្រើនត្រូវបាននាំមកដល់មន្ទីរពេទ្យនេះ។ ទោះជាយ៉ាងណាក៏ដោយ គាត់បាននិយាយថា ចំនួនអ្នកស្លាប់បានកើនឡើងទៅ10នាក់បន្ទាប់ពីមនុស្ស4នាក់ដែលរងរបួសធ្ងន់ធ្ងរបានស្លាប់។ក្រៅពីនេះ មនុស្ស12នាក់ស្លាប់ និងមនុស្សជាង80នាក់រងរបួសក្នុងការជ្រះជ្រើនជាមួយប៉ូលីសនៅតំបន់ហ្គីល់ហ្គីត - ប៉ាល់តិស្ថាននៅភាគខាងជើង នៅពេលប្រជនប示威ជាច្រើននាក់ ដែលត្រូវបានរំភើបដោយការវាយប្រហាររបស់អាមេរិក និងអ៊ីស្រាអែលចំពោះរដ្ឋអាហ្រណ៍អ៊ីរ៉ង់ បានវាយប្រហារការិយាល័យនៃក្រុមសង្កត់អង្គការសង្គ្រាមអង្គការសហប្រជាជន និងក្រុមអភិវឌ្ឍន៍ការសហប្រជាជន (UNDP) ដោយមន្រ្តីពង្រឹងក្នុងតំបន់ អាស្ការអាលី បាននិយាយ។អ្នកនិយាយរដ្ឋាភិបាល សហប៊ីរ មិនបាននិយាយថាអ្នកប្រើប្រាស់ទាំងអស់ក្នុងក្រុមអង្គការទាំងនេះសុវត្ថិ។ គាត់បាននិយាយថា អ្នកប示威បានជ្រះជ្រើនជាមួយប៉ូលីសជាច្រើនក្នុងតំបន់ផ្សេងៗនៅតំបន់នេះ ជំរុញការិយាល័យនៃអង្គភាពសង្គមក្នុងតំបន់ ហើយបានដុតផ្ទះប៉ូលីស។ ទោះជាយ៉ាងណាក៏ដោយ គាត់បាននិយាយថា មន្រ្តីពង្រឹងបាន_DEPLOY_troops និងធ្វើឱ្យស្ថានភាពត្រូវបានគ្រប់គ្រង។អង្គការប្រទេសអាមេរិកនៅប៉ាគីស្ថានបាននិយាយក្នុងការផ្សាយនៅលើ តាមដានថាវានឹងត្រួតពិនិត្យការរាយការណ៍នៃការប示威ដែលកំពុងកើតឡើងនៅការិយាល័យសាធារណៈអាមេរិកនៅការ៉ាជី និងឡាហោរ និងការស្នើសុំបង្កើតការប示威បន្ថែមនៅការិយាល័យប្រទេសអាមេរិកនៅអ៊ីស្លាម៉ាបាដ និងការិយាល័យសាធារណៈនៅពេសាវ៉ារ។វានឹងផ្តល់សេចក្តីបណ្តឹងសម្រាប់អ្នកជនជាតិអាមេរិកនៅប៉ាគីស្ថានត្រួតពិនិត្យព័ត៌មានក្នុងស្រុកក្នុងតំបន់ ទុកចិត្តអំពីបរិស្ថានជុំវិញខ្លួន លំហាត់កន្លែងចំនួនមនុស្សច្រើន និងរក្សាទុកការចុះឈ្មោះធ្វើដំណើរការរបស់ពួកគេជាមួយរដ្ឋាភិបាលអាមេរិកថ្មីៗ។បង្អួចប៉ូងការិយាល័យអាមេរិកបានបំបែកនៅការ៉ាជី ដែលជាជ្រុងនៃតំបន់ស៊ីន្ធដនៅភាគខាងត្បូង និងជាជ្រុងធំបំផុតនៃប៉ាគីស្ថាន មន្រ្តីពង្រឹងខ្ពស់ អ៊ីរ្វាន់ ប៉ាលូចបាននិយាយថា អ្នកប示威បានវាយប្រហារខ្លះពេលប៉ះពាល់នៅព្រំដែនការិយាល័យអាមេរិក ដោយមកត្រូវបានបែកខ្ញែកក្រោយមក។គាត់បានបដិសេធនឹងការរាយការណ៍ថាផ្ទះការិយាល័យណាមួយនៃការិយាល័យនេះត្រូវបានដុតផ្ទះ។ ទោះជាយ៉ាងណាក៏ដោយ គាត់បាននិយាយថា អ្នកប示威បានដុតផ្ទះប៉ូលីសនៅជិត ហើយបានបំបែកបង្អួចប៉ូងនៃការិយាល័យមុនពេលកម្មforcesង្គោះសន្តិសុខបានមក និងបានយកគ្រប់គ្រងឡើងវិញ។ការប示威នៅតំបន់ជុំវិញការិយាល័យបានបន្តរយៈពេលជាច្រើនម៉ោង ជាមួយក្មេងជនចំនួនមួយ ពាក់មុខដោយខ្លួនពួកគេ បោះថ្មលើអ្នកធ្វើការអនុសាសន៍ ហើយបានសន្យាបានឈានដល់ការិយាល័យ ដែលមានអ្នកប៉ូលីស និងអ្នកប្រព័ន្ធដង្ហើមចំនួនរាប់រយត្រូវបាន_DEPLOY។ អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។ ការជ្រះជ្រើនបានជំរុញការិយាល័យក្រោមក្រោមប្រធានមន្រ្តីក្រោមក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក្រោមខាងក

Tomahawks, យន្តហោះបំផ្ទុះសម្ងាត់ B-2 និងឌ្រូនប្រយុទ្ធមក ឆ្លងការ ថាក់ទាំងអ៊ីរ៉ង់ជាង ១០០០ ពីតុក្ក ក្នុងការហجومរហ័សក្នុងរយៈពេល ២៤ ម៉ោង

ខែមីនា 2, 2026 admin

(SeaPRwire) - កងទ័ពសហរដ្ឋអាមេរិកបានចាប់ផ្តើមការវាយប្រហារយោធាដ៏ទូលំទូលាយលើគោលដៅរបស់អ៊ីរ៉ង់នៅថ្ងៃសៅរ៍ ដោយបញ្ចេញថាមពលអាកាស សមុទ្រ និងមីស៊ីលដ៏ច្រើនជាងគេក្នុងប្រតិបត្តិការដែលសម្របសម្រួលជាមួយអ៊ីស្រាអែល។ប្រតិបត្តិការនេះ — ដែលត្រូវបានគេហៅថា "Operation Epic Fury" — បានចាប់ផ្តើមនៅម៉ោង ១:១៥ ព្រឹក ហើយបានវាយប្រហារលើទីតាំងជាង ១,០០០ ទីក្នុងរយៈពេល ២៤ ម៉ោងដំបូងរបស់វា យោងតាមការបញ្ជាការកណ្តាលសហរដ្ឋអាមេរិក (CENTCOM)។ លេខាដឹកនាំខ្ពស់របស់អ៊ីរ៉ង់ Ali Khamenei និងមន្ត្រីកំពូលរបស់រජímeជាច្រើនរូបត្រូវបានលុបបំបាត់ក្នុងការវាយប្រហារទាំងនោះ។ការបាញ់មីស៊ីលទាំងនេះរួមមានយន្តហោះបំផ្ទុះសម្ងាត់ B-2 យន្តហោះចម្បាំង F-22 និង F-16 យន្តហោះវាយប្រហារ A-10 យន្តហោះសង្គ្រាមអេឡិចត្រូនិក EA-18G និងវេទិការព្រមានដំបូង និងទំនាក់ទំនងតាមអាកាសជាច្រើនប្រភេទ យោងតាម CENTCOM ។ប្រព័ន្ធការពារមីស៊ីល រួមទាំងឧបករណ៍រារាំង Patriot និងប្រព័ន្ធការពារមីស៊ីលប្រឆាំងបាឡីសទីស THAAD ត្រូវបានដាក់ប្រើក្នុងប្រតិបត្តិការនេះ។ទ្រព្យសម្បត្តិផ្សេងទៀតរួមមានយន្តហោះស៊ើបអង្កេត RC-135 ដ្រូន MQ-9 Reaper ប្រព័ន្ធប្រមុន HIMARS , ឆលកុម្មង់ដឹកមីស៊ីលដឹកនាំ យន្តហោះបំពេញប្រេង និងយន្តហោះដឹកជញ្ជូន C-17 និង C-130 យោងតាម CENTCOM ។ការបញ្ជាការក៏បានចេញរូបភាពមីស៊ីលក្រុយស Tomahawk ក៏ដូចជា roaring into combat យោងតាម Reuters ។CENTCOM ក៏បានបញ្ជាក់បន្ថែមថាវាបានដាក់ប្រើ ក្នុងសង្គ្រាមជាលើកដំបូង។ប្រព័ន្ធវាយប្រហារសង្គ្រាមដោយឧបករណ៍អន្តរជាតិដោយថ្លៃទាប — ដែលត្រូវបានគេហៅថា LUCAS — ត្រូវបានគំរូយកពីដ្រូន Shahed របស់អ៊ីរ៉ង់។"Task Force Scorpion Strike របស់ CENTCOM — ជាលើកដំបូងក្នុងប្រវត្តិសាស្ត្រ — កំពុងប្រើដ្រូនវាយប្រហារតែមួយទិសក្នុងសង្គ្រាមកំឡុង Operation Epic Fury," CENTCOM បានសរសេរនៅលើ X ។ "ដ្រូនទាំងនេះដែលថ្លៃទាប ដែលគំរូយកពីដ្រូន Shahed របស់អ៊ីរ៉ង់ ឥឡូវនេះកំពុងផ្តល់ការសងសឹកដែលផលិតដោយអាមេរិក។"ដ្រូន LUCAS ដែលត្រូវបានបង្កើតឡើងដោយក្រុមហ៊ុនវិស្វកម្ម SpektreWorks ដែលមានមូលដ្ឋាននៅ Arizona អាចត្រូវបានបាញ់ចេញពីកាតាប៊ុល យាន ឬវេទិកាដីដែលអាចផ្លាស់ទីបាន យោងតាម .ដ្រូននីមួយៗមានតម្លៃប្រហែល 35,000 ដុល្លារ យោងតាម Reuters ។ការវាយប្រហារទាំងនោះបានគោលដៅលើមជ្ឈមណ្ឌលបញ្ជា និងការគ្រប់គ្រង មជ្ឈមណ្ឌលរួមរបស់កងការពារបដិវត្តអ៊ីស្លាម (IRGC) និងមជ្ឈមណ្ឌលកងទ័ពអាកាស ព្រមទាំងប្រព័ន្ធការពារអាកាសរួមបញ្ចូលគ្នា ទីតាំងមីស៊ីលបាឡីសទីស ឆល និងស៊ុមម៉ារីនរបស់អ៊ីរ៉ង់ ទីតាំងមីស៊ីលប្រឆាំងឆល និង យោងតាម CENTCOM ។អ៊ីរ៉ង់បានសងសឹកដោយបាញ់មីស៊ីលជាច្រើនរលកនៅទូទាំងមជ្ឈឹមបូព៌ា ដោយគោលដៅលើមូលដ្ឋានសហរដ្ឋអាមេរិកដ៏សំខាន់នៅកាតារ បាហ្រីន ខុយវ៉េត និងអារ៉ាប់រួមជាតិ យោងតាម Business Insider ។សមាជិកកងទ័ពសហរដ្ឋអាមេរិក ៣ នាក់ត្រូវបានសម្លាប់ ហើយ ៥ នាក់ផ្សេងទៀតត្រូវបាន "រងរបួសធ្ងន់ធ្ងរ" ក្នុងប្រតិបត្តិការ Operation Epic Fury យោងតាម CENTCOM ដែលបាននិយាយនៅព្រឹកថ្ងៃអាទិត្យ។ ប្រតិបត្តិការយោធារួមនេះត្រូវបានរំពឹងថានឹងបន្តអស់រយៈពេលជាច្រើនថ្ងៃ។CENTCOM មិនបានឆ្លើយតបភ្លាមៗទៅនឹងការស្នើសុំយោបល់របស់ Digital ទេ។Reuters និង Michael Dorgan របស់ Digital បានរួមចំណែកដល់របាយការណ៍នេះ។ អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។

WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

ខែមីនា 2, 2026 admin

RAHWAY, NJ and TOKYO, Mar 2, 2026 - (JCN Newswire via SeaPRwire.com) - Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan), Merck & Co., Inc., Rahway, NJ, USA’s first-in-class oral hypoxiainducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. These data are being presented as a late-breaking oral abstract at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (abstract #LBA417) and are included in the official ASCO GU Press Program.At a pre-specified interim analysis with a median follow-up of 29.0 months (range, 19.3-49.2), WELIREG plus LENVIMA demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS), reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. For WELIREG plus LENVIMA, the median PFS was 14.8 months (95% CI, 11.2-16.6) versus 10.7 months (95% CI, 9.2-11.1) for cabozantinib. A trend toward improvement in overall survival (OS), the trial’s other primary endpoint, was also observed for WELIREG plus LENVIMA (HR=0.85 [95% CI, 0.68-1.05]; p=0.06075). The median OS was 34.9 months (95% CI, 27.5-NR) for WELIREG plus LENVIMA versus 27.6 months (95% CI, 24.0- 31.4) for cabozantinib. The trial is continuing, and OS will be evaluated at a subsequent analysis per the clinical trial protocol.Based on data from the LITESPARK-011 trial, the U.S. Food and Drug Administration (FDA) has accepted two supplemental New Drug Applications (sNDA) for review seeking approval for WELIREG plus LENVIMA for the treatment of adult patients with advanced RCC with a clear cell component following a PD-1 or PD-L1 inhibitor. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action date, of October 4, 2026, for both the WELIREG and LENVIMA sNDAs. Merck & Co., Inc., Rahway, NJ, USA and Eisai will also discuss these data with regulatory authorities worldwide to support potential submissions outside the United States.“Choosing the right treatment for patients with advanced renal cell carcinoma after immunotherapy has been an ongoing challenge, and treatment options in this setting had not previously been evaluated against a current standard of care tyrosine kinase inhibitor in a Phase 3 trial,” said Dr. Robert Motzer, Principal Investigator and Genitourinary Medical Oncologist, Memorial Sloan Kettering Cancer Center. “The LITESPARK-011 study demonstrated a 30% reduction in the risk of disease progression or death with belzutifan plus lenvatinib compared to cabozantinib, and 52.6% of patients experienced a response to treatment. These findings mark a critical step forward for these patients.”“The LITESPARK-011 trial highlights the potential of this first-of-its-kind combination regimen to deliver a meaningful benefit for patients with advanced renal cell carcinoma whose disease progresses after PD-1/L1 therapy,” said Dr. M. Catherine Pietanza, Vice President, Global Clinical Development, MSD Research Laboratories. “These WELIREG plus LENVIMA data demonstrate important progress for patients with advanced renal cell carcinoma and reinforce our commitment to improving the lives of patients through innovative treatment strategies.”“The LITESPARK-011 results reinforce LENVIMA's established role in renal cell carcinoma and highlight the potential of this novel combination to address an area of significant unmet need,” said Dr. Corina Dutcus, Senior Vice President, Oncology Global Clinical Development Lead at Eisai. “The acceptance of this regulatory filing is an important milestone, and we remain committed to working toward approval to bring this option to patients as soon as possible. We are grateful to the patients, their families, and the investigators, whose dedication made this research possible.”Additional findingsData for objective response rate (ORR) and duration of response (DOR), two key secondary endpoints, were also reported. At the first interim analysis with a median follow-up of 19.6 months (range, 9.9-39.8), WELIREG plus LENVIMA met ORR, demonstrating a statistically significant improvement compared to cabozantinib. A confirmed ORR of 52.6% (95% CI, 47.3-57.7) was observed for WELIREG plus LENVIMA versus 39.6% (95% CI, 34.6-44.8) for cabozantinib. At the second interim analysis with a median follow-up of 29.0 months, the median DOR was 23.0 months (95% CI, 2.0-44.3+) for WELIREG plus LENVIMA versus 12.3 months (95% CI, 1.8+-35.9+) for cabozantinib.WELIREG plus LENVIMA was administered to 370 patients and cabozantinib was administered to 371 patients. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 71.6% of patients receiving WELIREG plus LENVIMA versus 65.8% of patients receiving cabozantinib. Adverse events led to treatment discontinuation in 11.1% of patients receiving WELIREG plus LENVIMA and in 11.3% of patients receiving cabozantinib, respectively. Serious adverse events were observed in 51.6% of patients receiving WELIREG plus LENVIMA versus 43.9% of patients receiving cabozantinib, and AEs led to death in 5.4% of patients (two were treatment-related: thrombotic microangiopathy [n=1] and pneumonitis [n=1]) versus 3.2% (one was treatment-related: hemoptysis [n=1]) of patients, respectively.LITESPARK-011 is part of a comprehensive late-stage clinical development program for WELIREG comprised of several Phase 2 and Phase 3 trials in pheochromocytoma and paraganglioma, von HippelLindau disease-associated neoplasms and RCC. The Phase 3 LITESPARK-012 trial is evaluating the addition of WELIREG to KEYTRUDA® (pembrolizumab), Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, plus LENVIMA in the first-line advanced RCC disease setting.WELIREG is approved in the U.S., European Union (EU), Japan and other countries for the treatment of adult patients with advanced clear cell RCC following a PD-1/PD-L1 inhibitor and 1-2 VEGFTKIs based on results from the Phase 3 LITESPARK-005 trial.KEYTRUDA plus LENVIMA is approved in the U.S., the EU, Japan and other countries for the treatment of advanced RCC. Lenvatinib is approved as KISPLYX for advanced RCC in the EU.LENVIMA in combination with everolimus is approved in the U.S., EU and other regions for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy.Dr. Motzer has provided consulting and advisory services for Merck & Co., Inc., Rahway, NJ, USA and Eisai.About LITESPARK-011LITESPARK-011 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT04586231) evaluating WELIREG in combination with LENVIMA compared to cabozantinib for the treatment of patients with advanced clear cell RCC that has progressed on or after anti-PD-1/L1 therapy. The dual primary endpoints are PFS per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by blinded independent central review (BICR) and OS. Key secondary endpoints include ORR per RECIST v1.1 as assessed by BICR, DOR per RECIST v1.1 as assessed by BICR, and safety. The trial enrolled 747 patients who were randomized to receive WELIREG (120 mg orally once daily) plus LENVIMA (20 mg orally once daily) or cabozantinib (60 mg orally once daily).About renal cell carcinomaRenal cell carcinoma is the most common type of kidney cancer, with about nine out of 10 kidney cancer diagnoses being RCC.1 In 2022, there were about 435,000 new cases of kidney cancer and approximately 156,000 deaths from the disease worldwide.2 RCC is about twice as common in men as in women.1 Most cases of RCC are discovered incidentally during imaging tests for other abdominal diseases. Approximately 30% of patients with kidney cancer are diagnosed at an advanced stage.3About Merck & Co., Inc., Rahway, NJ, USA’s research in genitourinary cancersMerck & Co., Inc., Rahway, NJ, USA is advancing research aimed at helping transform the treatment landscape and broaden options for people with genitourinary (GU) cancers, including bladder, kidney and prostate cancers. Globally, GU cancers account for an estimated 2.6 million new cancer diagnoses each year, equaling over 1 in 8 of all cancer incidences. Through a robust clinical development program with more than 50 clinical trials evaluating more than 22,000 patients around the world, Merck & Co., Inc., Rahway, NJ, USA is investigating the potential of several portfolio medicines and pipeline assets, leveraging multiple novel combination strategies, across various stages of disease, to help address unmet needs in GU cancers.About WELIREG® (belzutifan) 40 mg tablets, for oral useWELIREG, Merck & Co., Inc., Rahway, NJ, USA’s first-in-class hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, is an orally administered small-molecule designed to reduce transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. By inhibiting HIF-2α signaling, WELIREG aims to disrupt key pathways certain tumors may use to adapt to low-oxygen conditions, including those that help promote abnormal blood vessel formation and support tumor survival.WELIREG has demonstrated antitumor activity in certain von Hippel-Lindau (VHL) disease-associated tumors, renal cell carcinoma and in pheochromocytoma or paraganglioma. As part of a broader clinical program, Merck & Co., Inc., Rahway, NJ, USA continues to research WELIREG monotherapy and combination approaches for people with genitourinary, breast and gynecologic cancers across a range of treatment settings to further define where HIF-2α inhibition may provide clinical benefit and to better understand which patients are most likely to respond.About LENVIMA® (lenvatinib); available as 10 mg and 4 mg capsulesLENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below.Thyroid cancer- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable thyroid cancerThe United States: The treatment of patients with locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (DTC)Europe: The treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)Hepatocellular carcinoma- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable hepatocellular carcinomaThe United States: The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)Europe: The treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy- Indication in combination with KEYTRUDA (generic name: pembrolizumab) and transarterial chemoembolization(Approved in China)Thymic carcinoma- Indication as monotherapy (Approved in Japan)Japan: Unresectable thymic carcinomaRenal cell carcinoma (In Europe other than the United Kingdom, the agent was launched under the brand name Kisplyx®)- Indication in combination with everolimus(Approved mainly in the United States, Europe and Asia)The United States: The treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapyEurope: The treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Radically unresectable or metastatic renal cell carcinomaThe United States: The first-line treatment of adult patients with advanced renal cell carcinomaEurope: The first-line treatment of adult patients with advanced renal cell carcinomaEndometrial carcinoma- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapyThe United States: The treatment of patients with advanced endometrial carcinoma that is pMMR or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiationEurope: The treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery.About the Eisai and Merck & Co., Inc., Rahway, NJ, USA Strategic CollaborationIn March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA, known as MSD outside of the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and cocommercialization of LENVIMA. Under the agreement, the companies jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA, and HIF-2α inhibitor, WELIREG.Eisai’s focus on cancerEisai acknowledges “Oncology” as one of its key strategic areas, and will continue to focus on the discovery and development of anti-cancer drugs within drug discovery domains including “microenvironment”, “protein integrity and homeostasis”, and “cell lineage and cell differentiation” under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancersAbout EisaiEisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (U.S. and global), LinkedIn (for U.S. and EMEA) and Facebook (global).Merck & Co., Inc., Rahway, NJ, USA’s Focus on CancerEvery day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncology.About Merck & Co., Inc., Rahway, NJ, USAAt Merck & Co., Inc., Rahway, NJ, USA, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on  X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USAThis news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).(1) American Cancer Society, “What Is Kidney Cancer” https://www.cancer.org/cancer/types/kidney-cancer/about/what-is-kidney-cancer.html(2) International Agency for Research on Cancer, World Health Organization. “Kidney fact sheet” Cancer Today, GLOBOCAN 2022. https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf(3) E. Esterberg et al. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer April 2024, Vol. 22, No. 2, 115–125. https://www.sciencedirect.com/science/article/pii/S1558767323002203Merck & Co., Inc., Rahway, NJ, USAMedia RelationsJulie Cunningham: +1-(617) 519-6264John Infanti: +1-(609) 500-4714Merck & Co., Inc., Rahway, NJ, USAInvestor RelationsPeter Dannenbaum: +1-(732) 594-1579Steven Graziano: +1-(732) 594-1583Eisai Co., Ltd.Public Relations:+81-(0)3-3817-5120Eisai Co., Ltd.Investor Relations:+81-(0) 3-3817-5122 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

The Tomorrow Company Launches With a Bold Mandate to Build the Infrastructure Layer of the AI-Native Financial Era.

ខែមីនា 2, 2026 admin

Vancouver, BC, Mar 2, 2026 - (ACN Newswire via SeaPRwire.com) - The Tomorrow Company (“TMRW”) today announced the completion of its strategic merger with Carbon Distributed Technologies AG (“CUT”) and Plato Technologies Inc., forming an integrated Web3 infrastructure platform positioned at the convergence of artificial intelligence, tokenized real-world assets, and programmable climate markets.The Company is launching with a clear conviction: the next decade of value creation in digital finance will belong to those who build and own infrastructure — not interfaces. Systems that are programmable. Intelligence that is embedded. Assets that are verifiable. Rails that institutions can scale on.Global markets are entering a structural transformation. Artificial intelligence is rapidly becoming embedded into capital allocation, enterprise operations, and regulatory oversight. Digital assets are evolving from trading vehicles into programmable utility frameworks capable of moving value instantly and transparently. Climate accountability is moving from narrative commitments to measurable, auditable instrumentation.The Tomorrow Company is designed to operate at the intersection of these structural shifts — and to grow with them. The merger unites two powerful and complementary platforms.CUT Carbon Distributed Technologies AG contributes a tokenized carbon utility framework structured around verifiability, traceability, and retirement mechanics. Built within Liechtenstein’s Blockchain Act framework and deployed on Ethereum Mainnet, CUT’s model emphasizes measurable CO₂ reduction linkage and immutable audit trails across issuance, transfer, and retirement. As regulators, institutions, and global enterprises demand higher standards of disclosure and impact validation, programmable carbon infrastructure becomes foundational to next-generation capital markets.Paul Thomson, Co-Founder of CUT Carbon Distributed Technologies AG, commented:“Tokenized commodities are moving from intention to instrumentation. For tokenized carbon credits, what matters now is verifiability—traceable assets, defensible controls, and retirement mechanics that stand up to real scrutiny. By integrating into The Tomorrow Company’s broader infrastructure platform, we believe we can accelerate adoption and bring institutional-grade carbon instrumentation to global markets.”Complementing this climate utility layer is Plato Technologies Inc., which brings an AI-driven intelligence engine purpose-built to convert fragmented global data into deployable, decision-ready workflows. Plato’s vertically focused intelligence products are designed for repeat enterprise usage and global distribution, with an operating discipline centered on scalable infrastructure and cost efficiency.Bryan Feinberg, CEO and Founder of Plato Technologies Inc., stated:“AI is only transformative when it moves from insight to execution. This merger connects measurable data verticals with a distribution-driven intelligence engine designed to operate at scale. The opportunity ahead is not incremental — it is to embed AI directly into the infrastructure layer of emerging digital markets.”The Tomorrow Company is structured as a diversified Web3 infrastructure holding platform with multiple reinforcing value engines. The strategy extends beyond a single asset class or vertical. Leadership intends to expand tokenized asset frameworks beyond carbon into additional real-world asset categories where verifiability and programmability unlock new liquidity. The Company plans to accelerate the deployment of vertical AI intelligence products across sectors where data fragmentation creates inefficiencies. It also intends to pursue selective acquisitions and integrations aligned with durable utility, regulatory alignment, and institutional capital flows.Management believes that over the coming years, the convergence of AI and tokenization will redefine how capital is raised, allocated, verified, and measured. Markets will increasingly reward platforms that can demonstrate programmable accountability, embedded intelligence, and infrastructure resilience. TMRW’s long-term objective is to build a compounding portfolio of infrastructure assets that operate beneath market cycles — generating value through adoption, integration, and scale rather than volatility.The Company’s growth roadmap includes expanding institutional partnerships, deepening blockchain-native infrastructure capabilities, and deploying AI systems that integrate directly into financial and enterprise workflows. As tokenized real-world assets and AI-native markets expand globally, The Tomorrow Company aims to position itself as a foundational infrastructure layer — enabling new asset classes, accelerating measurable climate action, and embedding intelligence into digital capital flows.This launch represents the beginning of an expansion strategy, not its culmination. The leadership of The Tomorrow Company believes that the coming cycle will see a dramatic re-rating of infrastructure-layer platforms that combine regulatory alignment, programmable assets, and deployable AI systems. TMRW is entering the market with the ambition to help define that category.About The Tomorrow CompanyThe Tomorrow Company is a Web3 infrastructure and digital asset holding company focused on building foundational rails for the AI-native financial era. Through strategic acquisitions, tokenized utility frameworks, and vertically deployable intelligence products, TMRW seeks to architect scalable systems designed for institutional-grade adoption and long-term compounding growth.About CUT Carbon Distributed Technologies AGCUT Carbon Distributed Technologies AG operates CUT.eco, a tokenized carbon utility platform focused on verification, traceability, and transparent retirement mechanics under Liechtenstein’s blockchain regulatory framework.About Plato Technologies Inc.Plato Technologies Inc. develops AI-powered, vertically focused intelligence products designed to transform aggregated global data into deployable workflows and scalable Web3 AI capabilities.Forward-Looking StatementsThis press release contains forward-looking statements relating to anticipated strategic benefits, expansion initiatives, market opportunities, and future performance. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. The Company undertakes no obligation to update such statements except as required by law.ContactBryan Feinberg / COO The Tomorrow Companybf@tmrw-digital.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com